Literature DB >> 9292427

In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

P W Nelson1, M Lozano-Chiu, J H Rex.   

Abstract

L-733,560 and L-743,872 are water-soluble pneumocandins with potent antifungal activity. By beginning with the NCCLS M27-T method and varying test format (microdilution vs macrodilution), time of reading (24 h vs 48 h), and test medium (RPMI 1640 vs Antibiotic Medium 3), we have demonstrated that the MICs for these compounds can be altered significantly: the microdilution format, reading after 24 h and use of Antibiotic Medium 3 all reduced the measured MIC. No cross-resistance was demonstrated with either fluconazole or amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292427

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  26 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.

Authors:  A H Groll; B M Gullick; R Petraitiene; V Petraitis; M Candelario; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.

Authors:  M Del Poeta; M C Cruz; M E Cardenas; J R Perfect; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

8.  Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.

Authors:  Thomas J Walsh; Peter C Adamson; Nita L Seibel; Patricia M Flynn; Michael N Neely; Cindy Schwartz; Aziza Shad; Sheldon L Kaplan; Maureen M Roden; Julie A Stone; Alisha Miller; Susan K Bradshaw; Susan X Li; Carole A Sable; Nicholas A Kartsonis
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

9.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.